Join
Live feed
·
PRReleasevia Quantisnow
Pharming Group N.V. ADS each representing 10 logo

Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026

ByQuantisnow·Wall Street's wire, on your screen.
PHAR· Pharming Group N.V. ADS each representing 10
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PHAR (Pharming Group N.V. ADS each representing 10) and more on Quantisnow.